Companies Dominating the COPD Treatment Market
- GlaxoSmithKline plc
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- AstraZeneca plc
- Boehringer Ingelheim International GmbH
- Novartis International AG
- Teva Pharmaceutical Industries Ltd.
- Mylan N.V.
- Merck & Co., Inc.
- Sunovion Pharmaceuticals Inc.
- Chiesi Farmaceutici S.p.A.
- Circassia Pharmaceuticals plc
Browse Key Market Insights with Data Illustration:
In the News
- AstraZeneca announced the acquisition of Caelum Biosciences, a US-based biotech developing novel medicines for chronic respiratory diseases like asthma and chronic obstructive pulmonary disease (COPD). This acquisition strengthens AstraZeneca's respiratory franchise and broadens their pipeline with promising late-stage assets.
- AstraZeneca and Merck announced a collaboration for a Phase 3 clinical trial evaluating Lynparza® (olaparib), a targeted therapy, in combination with gemcitabine and nab-paclitaxel for the treatment of patients with metastatic pancreatic cancer harboring BRCA mutations. This partnership seeks to expand treatment options for this aggressive cancer with limited therapeutic options.
